spironolactone
Trade name: aldactone
Approved
Jan 21, 1960
Spironolactone is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics. On its own, spironolactone is only a weak diuretic, but it can be combined with other diuretics. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgendered people. Spironolactone inhibits the effect of aldosterone by competing for intracellular aldosterone receptor in the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of action, taking several days to develop and similarly the effect diminishes slowly. Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule . Spironolactone bind to this mineralcorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys. Spironolactone is used primarily to treat low-renin hypertension, hypokalemia, and Conn's syndrome. — NCATS
Clinical trial activity
226 trials · 248 clinical orgs · 31 marketing orgs
Earliest trial started Jan 1, 1985 (NCT00001202)
Timeline
1960s
- Jan 21, 1960
G D Searle — Earliest FDA Approval
- Jan 21, 1960
G D Searle — NDA Secondary Org
- Jan 21, 1960
G D Searle — NDA Organization
- Jan 21, 1960
Pfizer — NDA Secondary Org
1970s
- Aug 3, 1979
Mylan — Marketing Organization
1980s
- May 7, 1980
Ivax — Marketing Organization
- Jul 10, 1980
CASI Pharmaceuticals, Inc. — Marketing Organization
- Jul 10, 1980
Chartwell Pharmaceuticals — Marketing Organization
- Jul 10, 1980
Fosun — Marketing Organization
- Jan 28, 1981
Mutual Pharmaceutical — Marketing Organization
- Feb 3, 1981
PHARMOBEDIENT — Marketing Organization
- Feb 23, 1981
Watson Pharmaceuticals — Marketing Organization
- Dec 14, 1981
Vanguard — Marketing Organization
- Aug 4, 1982
Lederle — Marketing Organization
- Aug 4, 1982
American Cyanamid — Marketing Organization
- Aug 15, 1983
Ascot Pharmaceuticals — Marketing Organization
- Jan 1, 1985
Earliest Phase 2 Sponsor(trial)
- Aug 26, 1985
Superpharm — Marketing Organization
- Nov 6, 1985
Puracap Pharmaceutical — Marketing Organization
- Jul 23, 1986
Sun Pharmaceuticals — Marketing Organization
1990s
- Jul 29, 1999
Actavis — Marketing Organization
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2005
Earliest Phase 3 Sponsor(trial)
- Aug 29, 2006
Oxford Pharmaceuticals — Marketing Organization
2010s
- Jul 2, 2010
Amneal Pharmaceuticals — Marketing Organization
- Mar 6, 2014
Aurobindo Pharma — Marketing Organization
- Apr 23, 2014
Jubilant Innovation Ltd. — Marketing Organization
- Sep 19, 2016
Accord Research — Marketing Organization
- Aug 4, 2017
CMP Therapeutics Ltd — NDA Secondary Org
- Jul 18, 2018
Zydus Discovery DMCC — Marketing Organization
2020s
- Jan 23, 2025
Graviti Pharmaceuticals — Marketing Organization
- Feb 21, 2025
Hetero Labs Ltd — Marketing Organization
- Jul 25, 2025
Annora Pharma — Marketing Organization
Indications
Approved for
Studied for
- Acanthosis Nigricans · Phase 2
- Acne Vulgaris · Phase 4
- Acute Kidney Injury · Phase 3
- Adrenocorticotropic Hormone · Phase 2
- Albuminuria · Phase 2
- Alcoholism · Phase 4
- Alopecia · Phase 4
- Alzheimer Disease · Phase 4
- Anesthesia and Analgesia · Phase 3
- Aortic Stenosis, Subvalvular · Phase 3
- Arrhythmias, Cardiac · Phase 4
- Arthritis, Rheumatoid · Phase 3
- Ascites · Phase 4
- Atherosclerosis · Phase 4
- Atrial Fibrillation · Phase 4
- Autism Spectrum Disorder · Phase 2/Phase 3
- Blood Pressure · Phase 4
- Breast Neoplasms · Phase 2
- Bronchopulmonary Dysplasia · Phase 2/Phase 3
- Carcinoma, Hepatocellular · Phase 3
- Cardiomyopathies · Phase 4
- Cardiomyopathy, Alcoholic · Phase 4
- Cardiomyopathy, Dilated · Phase 3
- Cardiomyopathy, Hypertrophic · Phase 4
- Cardio-Renal Syndrome · Phase 4
- Cardiotoxicity · Phase 4
- Cardiovascular Diseases · Phase 4
- Central Serous Chorioretinopathy · Phase 1/Phase 2
- Cerebral Hemorrhage · Phase 2
- Cognitive Dysfunction · Phase 4
- Coronary Disease · Phase 2
- Coronavirus Infections · Phase 3
- Cortisone · Phase 2
- COVID-19 · Phase 3
- Critical Illness · Phase 2/Phase 3
- Cyclosteroids · Phase 2
- Dermatology · Phase 2
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Nephropathies · Phase 4
- Diabetic Retinopathy · Phase 2/Phase 3
- Drug Interactions · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Generic · Phase 1
- Drugs, Investigational · Phase 3
- Dry Eye Syndromes · Early Phase 1
- Edema · Phase 4
- Endomyocardial Fibrosis · Phase 4
- Essential Hypertension · Phase 2
- Fatty Liver · Phase 2
- Fibrosis · Phase 4
- Gender Dysphoria · Phase 1
- Genetic Predisposition to Disease · Phase 3
- Glomerulonephritis · Phase 2/Phase 3
- Glucocorticoids · Phase 2
- Glucose Intolerance · Phase 3
- Hair · Phase 2
- Healthy Volunteers · Phase 4
- Heart Defects, Congenital · Phase 2
- Heart Diseases · Phase 3
- Heart Failure, Diastolic · Phase 4
- Heart Failure, Systolic · Phase 4
- Heart Ventricles · Phase 1/Phase 2
- Hidradenitis Suppurativa · Phase 4
- HIV · Phase 1
- HIV Infections · Phase 4
- Hydroxymethylglutaryl-CoA Reductase Inhibitors · Phase 4
- Hyperaldosteronism · Phase 4
- Hyperandrogenism · Early Phase 1
- Hyperkalemia · Phase 4
- Hypertension, Portal · Phase 4
- Hypertension, Pregnancy-Induced · Phase 2
- Hypertension, Pulmonary · Phase 4
- Hypoglycemia · Phase 4
- Infections · Phase 4
- Ischemic Stroke · Phase 2
- Kidney Diseases · Phase 4
- Kidney Failure, Chronic · Phase 4
- Kidney Transplantation · Phase 4
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Liver Cirrhosis · Phase 4
- Liver Cirrhosis, Alcoholic · Phase 4
- Liver Diseases · Phase 4
- Liver Transplantation · Phase 4
- Lung Diseases · Phase 2/Phase 3
- Lymphoma · Phase 2
- Macular Degeneration · Phase 2
- Melanosis · Phase 1
- Mineralocorticoid Receptor Antagonists · Phase 4
- Muscular Dystrophy, Duchenne · Phase 3
- Mutation · Phase 2/Phase 3
- Myocardial Infarction · Phase 3
- Neoplasms · Phase 4
- Nephritis, Hereditary · Phase 4
- Neuroblastoma · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 1/Phase 2
- Non-ST Elevated Myocardial Infarction · Phase 3
- Osteoarthritis, Knee · Phase 4
- Ovulation · Early Phase 1
- Periodontal Pocket · Phase 2/Phase 3
- Peripheral Arterial Disease · Phase 4
- Peritoneal Dialysis · Phase 4
- Pharmacokinetics · Phase 3
- Pharmacology · Phase 3
- Pneumonia, Viral · Phase 3
- Polycystic Ovary Syndrome · Phase 2/Phase 3
- Pre-Eclampsia · Phase 2
- Proteinuria · Phase 2/Phase 3
- Puberty · Early Phase 1
- Puberty, Precocious · Phase 2
- Pulmonary Arterial Hypertension · Phase 4
- Renal Dialysis · Phase 4
- Renal Insufficiency · Phase 4
- Renal Insufficiency, Chronic · Phase 4
- Respiratory Distress Syndrome · Phase 4
- Sarcoma · Phase 2
- Semen · Phase 4
- Severe Acute Respiratory Syndrome · Phase 2
- Sleep Apnea, Obstructive · Phase 4
- Spironolactone · Phase 2/Phase 3
- ST Elevation Myocardial Infarction · Phase 3
- Steroids · Phase 2
- Stroke · Phase 4
- Thoracic Surgery · Phase 3
- Transgender Persons · Phase 1
- Transsexualism · Phase 3
- Vascular Calcification · Phase 3
- Vascular Stiffness · Phase 4
- Ventricular Dysfunction, Left · Phase 4
Mechanism of action
- Mineralocorticoid receptorANTAGONIST
NR3C2 antagonist
Combination products
aldactazide
with hydrochlorothiazide
Also known as spironolactone/hydrochlorothiazide (25 mg/25 mg) film coated tablets from neolpharma.
Approval history
- approvedPriority reviewJan 21, 1960
Chemistry & pharmacology
SMILES
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13- Mol. weight
- 416.573 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaSpironolactone ↗
- NCATS27O7W4T232 ↗
- ChEMBLCHEMBL1393 ↗
Also known as
- abbolactone
- abbolactone
- abbolactone
- aldactone
- aldactone
- aldactone
- aldactone
- aldactone
- aldazide
- aldopur
- berlactone
- diatensec
- diatensec
- espironolactona
- espironolactona
- euteberol
- gx spironol
- laractone
- laractone
- lasilactone
- quimolactona
- spiretic
- spiretic
- spiroctan 100
- spiroctan 25
- spiroctan 50
- spirolactone
- spironolacton
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactone
- spironolactonum
- spironolactonum
- spironolattone
- spironolattone
- spirospare 100
- spirospare 25
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07304817 | Phase 2 | Feb 28, 2026 | Boehringer Ingelheim, University of Groningen |
| NCT07223502 | Phase 3 | Dec 1, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT07041281 | Phase 2 | Oct 16, 2025 | Harvard University, University of Pittsburgh |
| NCT07015671 | Phase 3 | Jul 1, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT07043634 | Phase 3 | Jun 15, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT07046975 | Phase 3 | Jun 15, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT06678685 | Phase 2/Phase 3 (Phase 3) | Oct 30, 2024 | Shandong University |
| NCT06523465 | Phase 4 | Sep 10, 2024 | People's Liberation Army of China |
| NCT06021860 | Phase 4 | Jun 30, 2024 | CMP Therapeutics Ltd |
| NCT06457074 | Phase 4 | Jun 4, 2024 | Changzhi Medical College, Chongqing Medical University, Southwest Medical University, Zhejiang University, Zhengzhou University |
| NCT06204640 | Phase 3 | Mar 1, 2024 | University of Caen-Normandie |
| NCT06499948 | Phase 4 | Feb 26, 2024 | Carol Davila University of Medicine and Pharmacy, Institutul Clinic Fundeni, Bucarest, Romania |
| NCT05807139 | Phase 1 | Jan 3, 2024 | National Institute on Drug Abuse (NIDA) |
| NCT06205407 | Phase 1 | Dec 26, 2023 | Pfizer |
| NCT06164379 | Phase 4 | Dec 16, 2023 | Jiao Tong University |
| NCT06035978 | Phase 4 | Nov 30, 2023 | University of Ostrava |
| NCT06004830 | N/A | Nov 6, 2023 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), Yale University |
| NCT06275763 | Phase 4 | Oct 20, 2023 | Instituto Nacional de Cardiologia de Laranjeiras, Medical University of Warsaw |
| NCT06005259 | Phase 4 | Oct 1, 2023 | University of Sao Paulo |
| NCT05995392 | Early Phase 1 (Phase 1) | Aug 31, 2023 | Yee, Richard W., M.D. |
Organizations
Research & Development (248)
Marketing (35)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Sep 19, 2016 |
| Actavis | For profit | MKTG | Jul 29, 1999 |
| American Cyanamid | For profit | MKTG | Aug 4, 1982 |
| Amneal Pharmaceuticals | For profit | MKTG | Jul 2, 2010 |
| Amneal Pharmaceuticals | For profit | SYN | Jul 11, 2022 |
| Amneal Pharmaceuticals | For profit | SYN | Sep 5, 2023 |
| Annora Pharma | For profit | MKTG | Jul 25, 2025 |
| Ascot Pharmaceuticals | For profit | MKTG | Aug 15, 1983 |
| Aurobindo Pharma | For profit | MKTG | Mar 6, 2014 |
| Aurobindo Pharma | For profit | SYN | Mar 6, 2014 |
| CASI Pharmaceuticals, Inc. | For profit | MKTG | Jul 10, 1980 |
| CMP Therapeutics Ltd | For profit | NDA2 | Aug 4, 2017 |
| Chartwell Pharmaceuticals | For profit | MKTG | Jul 10, 1980 |
| Fosun | For profit | MKTG | Jul 10, 1980 |
| G D Searle | For profit | NDA2 | Jan 21, 1960 |
| G D Searle | For profit | NDA | Jan 21, 1960 |
| Graviti Pharmaceuticals | For profit | MKTG | Jan 23, 2025 |
| Hetero Labs Ltd | For profit | MKTG | Feb 21, 2025 |
| Ivax | For profit | MKTG | May 7, 1980 |
| Jubilant Innovation Ltd. | For profit | MKTG | Apr 23, 2014 |
| Lederle | For profit | MKTG | Aug 4, 1982 |
| Mutual Pharmaceutical | For profit | MKTG | Jan 28, 1981 |
| Mylan | For profit | MKTG | Aug 3, 1979 |
| Oxford Pharmaceuticals | For profit | MKTG | Aug 29, 2006 |
| PHARMOBEDIENT | For profit | MKTG | Feb 3, 1981 |
| Parke-Davis | For profit | MKTG | — |
| Pfizer | For profit | NDA2 | Jan 21, 1960 |
| Puracap Pharmaceutical | For profit | MKTG | Nov 6, 1985 |
| Sun Pharmaceuticals | For profit | MKTG | Jul 23, 1986 |
| Superpharm | For profit | MKTG | Aug 26, 1985 |
| Upsher-Smith Laboratories | For profit | MKTG | — |
| Vanguard | For profit | MKTG | Dec 14, 1981 |
| Warner Chilcott | For profit | MKTG | — |
| Watson Pharmaceuticals | For profit | MKTG | Feb 23, 1981 |
| Zydus Discovery DMCC | For profit | MKTG | Jul 18, 2018 |